Purchase List
The company provides a procurement platform listing its products.
kelun.comCrawled Nov 17, 2026
The company provides a procurement platform listing its products.
The company implements policies to prevent insider trading.
The company operates a procurement platform for suppliers and partners.
The company displays its product offerings on its website.
Sichuan Kelun Pharmaceutical Co., Ltd. describes its ESG practices, founded in 1996. The company, listed on the Shenzhen Stock Exchange since 2010, specializes in intravenous solutions, high-tech drugs, and biotech. It operates an international ADC research platform and expands into the broader health sector.
The company monitors drug safety and adverse reactions.
The company, founded in 1996, specializes in pharmaceuticals, including intravenous solutions, generic drugs, small-molecule drugs, and biotech medicines. It lists on the Shenzhen Stock Exchange as 科伦药业(002422.SZ).
Kelun-Biotech’s **Sacituzumab Tirumotecan** demonstrates superior progression-free survival (PFS) compared to chemotherapy as a first-line (1L) treatment for advanced **triple-negative breast cancer (TNBC)**. The Phase 3 **OptiTROP-Breast03 trial** met its primary endpoint, validating the drug’s efficacy in unresectable or metastatic TNBC. This marks a potential shift in standard-of-care options for patients with this aggressive cancer subtype.
Kelun-Biotech presents three clinical study results at the 2026 ASCO Annual Meeting, including findings from the **OptiTROP-Lung05** trial. The study compares **sacituzumab tirumotecan (sac-TMT) plus pembrolizumab** against **pembrolizumab alone** as first-line treatment for **PD-L1-positive advanced non-small cell lung cancer (NSCLC)**. Results highlight the trial’s randomized, controlled phase III design, focusing on efficacy and safety outcomes in this patient population.
Crescent Biopharma receives regulatory clearances for two investigational new drug (IND) applications. The company’s **CR-001**, a PD-1 x VEGF bispecific antibody, and **CR-003**, an ITGB6-targeted antibody-drug conjugate (ADC), advance toward clinical trials for treating solid tumors. Both therapies target distinct mechanisms to address unmet needs in oncology.
Kelun-Biotech and Crescent Biopharma partner to advance **CR-001**, a PD-1 x VEGF bispecific antibody, and **SKB105**, an integrin beta-6-directed antibody-drug conjugate (ADC). The collaboration aims to develop and commercialize these oncology therapeutics in global markets and China.
Kelun-Biotech reports Phase II study results of its TROP2-targeted antibody-drug conjugate, sacituzumab tirumotecan, as a monotherapy for treating urothelial carcinoma. The findings appear in *The Annals of Oncology*, evaluating the drug’s efficacy and safety in patients with advanced bladder cancer. The study assesses sacituzumab tirumotecan’s potential as a novel treatment option for this aggressive malignancy.
Kelun-Biotech raises **US$250 million** through a placement of **5.92 million H shares** under its general mandate. The biotech firm, listed on the Hong Kong Stock Exchange (6990.HK), executes capital-raising measures to support operations. The transaction reflects investor confidence in the company’s growth strategy.